Palleon’s Convergence Platform is driven by the combined expertise of our world-class founding team in tumor glycoscience and human immunology. We have incorporated a range of technologies to overcome the historic scientific barriers that have made glycoscience a challenging area of study. Armed with a unique understanding of the differences in immune pattern recognition between humans and other species, we have integrated human biology into every step of the drug development process, including target validation, in vitro models, in vivo models, and translational research. We have assembled the core expertise needed to pioneer a new field in this complex area of biology. Our proprietary knowledge and first mover advantage will define Palleon’s leadership in this rapidly emerging area.
Palleon has several cancer drug discovery programs underway. Beyond oncology, other important areas where Glycoimmune Checkpoints may play a role include infectious diseases, neurodegeneration, inflammation, and fibrosis.